TY - JOUR
T1 - Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
AU - Mir, Muhammad A.
AU - Maurer, Matthew J.
AU - Ziesmer, Steven C.
AU - Slager, Susan L.
AU - Habermann, Thomas
AU - Macon, William R
AU - Link, Brian K.
AU - Syrbu, Sergei
AU - Witzig, Thomas
AU - Friedberg, Jonathan W.
AU - Press, Oliver
AU - LeBlanc, Michael
AU - Cerhan, James R.
AU - Novak, Anne
AU - Ansell, Stephen M.
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology.
PY - 2015/2/5
Y1 - 2015/2/5
N2 - Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.
AB - Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.
UR - http://www.scopus.com/inward/record.url?scp=84922358591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922358591&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-06-583369
DO - 10.1182/blood-2014-06-583369
M3 - Article
C2 - 25422100
AN - SCOPUS:84922358591
SN - 0006-4971
VL - 125
SP - 992
EP - 998
JO - Blood
JF - Blood
IS - 6
ER -